Study of Glucose Intolerance and Diabetes from Steroid and PEG-Asparaginase Treatment in Children and Teens with ALL and Lymphoma

What this Trial Is About

Researchers are studying children and adolescents aged 1 to 17.9 years with newly diagnosed acute lymphoblastic leukemia ALL or lymphoma to understand how treatment with steroids prednisolone or dexamethasone and possibly PEG-asparaginase affects blood sugar levels. While survival rates for these diseases are above 90%, the treatments can cause severe side effects including glucose intolerance and diabetes, which this study aims to monitor more closely. Participants will wear a glucose sensor under the skin to continuously measure blood sugar during treatment phases involving steroids and PEG-asparaginase. Blood samples will also be taken several times to assess insulin sensitivity and pancreatic function. The study will observe blood sugar changes during key treatment periods, including induction, consolidation, and delayed intensification phases, to better understand medication-induced diabetes and glucose intolerance. Throughout the study, participants will have regular visits for sensor replacement and blood tests aligned with their treatment schedule. Researchers will analyze continuous glucose monitoring data and blood test results to track blood sugar levels, insulin resistance, and beta cell function over time. The findings may help develop new guidelines for monitoring and managing blood sugar during treatment, potentially reducing long-term risks like type 2 diabetes and metabolic syndrome in survivors.

Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma